Annexon Inc (ANNX) - Total Assets
Based on the latest financial reports, Annexon Inc (ANNX) holds total assets worth $262.89 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Annexon Inc to assess how comfortably operating cash covers total debt obligations.
Annexon Inc - Total Assets Trend (2017–2025)
This chart illustrates how Annexon Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Annexon Inc for net asset value and shareholders' equity analysis.
Annexon Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Annexon Inc's total assets of $262.89 Million consist of 87.3% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Annexon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Annexon Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Annexon Inc's current assets represent 87.3% of total assets in 2025, an increase from 62.6% in 2017.
- Cash Position: Cash and equivalents constituted 58.4% of total assets in 2025, up from 37.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Annexon Inc Competitors by Total Assets
Key competitors of Annexon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Annexon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.35 | 7.99 | 29.60 |
| Quick Ratio | 6.35 | 7.99 | 29.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $192.33 Million | $234.62 Million | $294.11 Million |
Annexon Inc - Advanced Valuation Insights
This section examines the relationship between Annexon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.37 |
| Latest Market Cap to Assets Ratio | 3.01 |
| Asset Growth Rate (YoY) | -20.7% |
| Total Assets | $277.57 Million |
| Market Capitalization | $834.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Annexon Inc's assets at a significant premium (3.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Annexon Inc's assets decreased by 20.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Annexon Inc (2017–2025)
The table below shows the annual total assets of Annexon Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $277.57 Million | -20.71% |
| 2024-12-31 | $350.07 Million | +17.60% |
| 2023-12-31 | $297.67 Million | +4.41% |
| 2022-12-31 | $285.10 Million | -0.68% |
| 2021-12-31 | $287.04 Million | -19.36% |
| 2020-12-31 | $355.95 Million | +613.35% |
| 2019-12-31 | $49.90 Million | +3.63% |
| 2018-12-31 | $48.15 Million | +515.64% |
| 2017-12-31 | $7.82 Million | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more